Brolucizumab deemed noninferior to aflibercept for DME treatment, fewer injections required
November 12th 2021During the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dilsher Dhoot, MD, reported the results of the KESTREL and KITE in which brolucizumab was compared with aflibercept for treating diabetic macular edema.
Analyzing an investigational ophthalmic solution for treating presbyopia-related symptoms
December 13th 2020Michael R. Robinson, MD, Allergan, discusses the results from a study analyzing an investigational ophthalmic solution for treatment of symptoms associated with presbyopia presented during the virtual AAO 2020 meeting.
Drug delivery vs drops: Controlling postop pain, inflammation in cataract patients
December 8th 2020John A. Hovanesian, MD, discusses the highlights of his presentation on a clinical study evaluating dexamethasone vs prednisolone acetate 1% in controlling postop pain/inflammation in sequential cataract surgery patients.
AAO 2020: Fingolimod for MS offers disease control with no development of uveitis
November 15th 2020Bradley Smith, MD, presents at AAO 2020 on how fingolimod 0.5 mg, a first-line treatment for multiple sclerosis, may reduce both the number of relapses and disease progression in patients with relapsing-remitting MS as well as the incidence of uveitis.
AAO 2020: Drop-free prophylaxis regimen before cataract surgery lowers treatment burden with caveats
November 15th 2020During AAO 2020, Neal H. Shorstein, MD, explains how physicians at Kaiser Permanente have a streamlined regimen using a prophylactic drop-free drug before cataract surgery for more than a decade.
AAO 2020: Preventing cystoid macular oedema after cataract surgery
November 15th 2020Rudy Nuijts of the University Eye Clinic Maastricht, the Netherlands, discusses the highlights of his AAO 2020 presentation on a combination treatment regimen for lowering the incidence of cystoid macular oedema following category surgery.
AAO 2020: Alcon showcases advanced IOL technology for presbyopia
November 15th 2020Kristen Brotherson, vice president, US surgical marketing for Alcon, discusses some of the recent advances in cataract surgery-related technologies, including a new advanced lens for patients with presbyopia (AcrySof IQ Vivity IOL).
AAO 2020: Alimera highlights NEW DAY Study for sustained-release intravitreal implant
November 15th 2020Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.
AAO 2020: Headache paired with visual loss may require honing of detective skills
November 14th 2020During AAO 2020, Kathleeen B. Digre, MD, details how a headache in conjunction with visual loss is a scenario that requires an in-depth examination, including evaluation of the visual fields, pupils, and fundus to gather clues to the diagnosis.
AAO 2020: Autologous retinal transplant for larger macular holes gaining traction
November 14th 2020Tamer Mahmoud, MD, PhD, discusses autologous retinal transplant (ART) for macular holes, a procedure he developed, which is providing anatomic hole closure in the vast majority of cases as well as increases in visual acuity.
AAO 2020: Myopia progression slowed with multifocal and orthokeratology lenses
November 14th 2020In a presentation at the American Academy of Ophthalmology’s virtual 2020 annual meeting, Amy K. Hutchinson, MD, explained that while Myopia has been occurring at epidemic rates worldwide, research has found that the use of orthokeratology and multifocal contact lenses can provide clinically meaningful reductions in myopia progression.
AAO 2020: Considerations when using anti-VEGF for treating AMD
November 14th 2020Prof. Giovanni Staurenghi, chairman of the University Eye Clinic, Department of Biomedical and Clinical Sciences at the University of Milan’s Luigi Sacco Hospital, Italy, discusses his presentation from this year's AAO, including findings from the HARBOR study of macular atrophy in AMD patients treated with ranibizumab.
AAO 2020: Alcon virtual booth spotlights latest studies, retina product offerings
November 14th 2020Josh Anderson, head of U.S. retina sales and marketing for Alcon, outlines what attendees will learn including product updates, new technologies, and practice management materials for ophthalmologists and their patients during the COVID-19 pandemic.